Why the study?
Do circulating concentrations of Galectin-3 reflect endomyocardial Galectin-3 levels or cardiac fibrosis in patients with heart failure?
Do circulating concentrations of Galectin-3 reflect endomyocardial Galectin-3 levels or cardiac fibrosis in patients with heart failure?
Circulating Galectin-3 levels do not accurately reflect myocardial Galectin-3 levels or cardiac fibrosis in heart failure patients, limiting its utility as a direct systemic biomarker for these specific cardiac processes.
Answers are grounded in this paper and cite their sources.
Circulating Gal-3 should not guide fibrosis assessment; leaves open myocardial Gal-3 as inflammation marker.
The present study suggests that myocardial Gal-3 can be considered as a possible marker for both cardiac inflammation and fibrosis, depending on the pathogenesis of heart failure. However, circulating concentrations of Gal-3 do not seem to reflect endomyocardial Gal-3 levels or cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Besler et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: